July 21 (Reuters) -

Biogen will invest an additional $2 billion in its

existing manufacturing in North Carolina, the drugmaker said on

Monday, as it seeks to expand its presence in the U.S. amid

President Donald Trump's tariff threats.

The company said the investment will go to its manufacturing

plants in North Carolina's Research Triangle Park (RTP), which

produce its major therapies for multiple sclerosis and

Alzheimer's.

Biogen has invested about $10 billion in its North Carolina

manufacturing to date.

The drugmaker said it plans to continue investing in

multiple modalities and factories across its two campuses in

RTP.